Two Sigma Investments
CNTX icon

Two Sigma Investments’s Context Therapeutics CNTX Stock Holding History

Two Sigma Investments’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,844
Closed -$27.1K – 3245
2024
Q3 		$27.1K Hold
13,844
– – ﹤0.01% 3010
2024
Q2 		$27.8K Buy
+13,844
New +$23.9K ﹤0.01% 2923
2023
Q3 		– Sell
-26,839
Closed -$42.9K – 2983
2023
Q2 		$42.9K Sell
26,839
-28,849
-52% -$24.5K ﹤0.01% 2843
2023
Q1 		$31.3K Buy
55,688
+29,154
+110% +$22.1K ﹤0.01% 2810
2022
Q4 		$17.3K Sell
26,534
-29,997
-53% -$32.3K ﹤0.01% 2693
2022
Q3 		$63K Buy
+56,531
New +$102K ﹤0.01% 2292

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Two Sigma Investments's CNTX Position: Q4 2024 in Review

Two Sigma Investments sold out of Context Therapeutics (CNTX) in Q4 2024, closing a stake of 13,844 shares — an estimated $27.1K sold.

Two Sigma Investments first reported a position in CNTX in Q3 2022 and held it in 6 quarters. The position peaked at $63K in Q3 2022. 52 funds tracked by Wall St. Rank hold CNTX as of Q4 2024.

  • Two Sigma Investments reported no remaining Context Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Investments sold 13,844 Context Therapeutics shares in Q4 2024, an estimated $27.1K.
  • Two Sigma Investments first reported a position in Context Therapeutics in Q3 2022 and held it in 6 quarters.
  • Two Sigma Investments's Context Therapeutics position peaked at $63K in Q3 2022.
  • 52 funds tracked by Wall St. Rank held Context Therapeutics as of Q4 2024.

Based on Two Sigma Investments's 13F filing for Q4 2024, filed 14 Feb 2025.